SPECTRUM PHARMACEUTICALS, INC.

(SPPI)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
0.8800 USD   -1.18%
06/23SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
06/10SPECTRUM PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
06/02Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

05/12/2022 | 04:00pm EDT

Spectrum Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 15.44 million compared to USD 35.7 million a year ago. Basic loss per share from continuing operations was USD 0.09 compared to USD 0.25 a year ago. Diluted loss per share from continuing operations was USD 0.09 compared to USD 0.25 a year ago. Basic loss per share was USD 0.09 compared to USD 0.25 a year ago. Diluted loss per share was USD 0.09 compared to USD 0.25 a year ago.


© S&P Capital IQ 2022
All news about SPECTRUM PHARMACEUTICALS, INC.
06/23SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submission of Ma..
AQ
06/10SPECTRUM PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continued Listi..
AQ
06/02Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences
BU
05/26Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predic..
BU
05/26ASCO 2022 : Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and response..
PU
05/25SPECTRUM PHARMACEUTICALS : Current Corporate Presentation
PU
05/17SPECTRUM PHARMACEUTICALS INC Change in Directors or Principal Officers (form 8-K/A)
AQ
05/17SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial Statem..
AQ
05/17Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference
BU
05/12TRANSCRIPT : Spectrum Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
More news
Analyst Recommendations on SPECTRUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 7,30 M - -
Net income 2022 -90,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,74x
Yield 2022 -
Capitalization 155 M 155 M -
Capi. / Sales 2022 21,2x
Capi. / Sales 2023 1,38x
Nbr of Employees 164
Free-Float 90,2%
Chart SPECTRUM PHARMACEUTICALS, INC.
Duration : Period :
Spectrum Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPECTRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,88 $
Average target price 5,60 $
Spread / Average Target 536%
EPS Revisions
Managers and Directors
Thomas J. Riga President, CEO, CFO & Director
William L. Ashton Chairman
Francois Lebel Chief Medical Officer & Executive Vice President
Lyndah K. Dreiling Senior Vice President-Clinical Development
Dolatrai M. Vyas Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SPECTRUM PHARMACEUTICALS, INC.-30.71%155
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.67%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-13.38%18 371